Helen Ma1, Ardy Davarifar1, Jennifer E Amengual2. 1. Center for Lymphoid Malignancies, Division of Hematology and Oncology, Department of Medicine, Columbia University Medical Center, 51 West 51st Street, Suite 200, New York, NY, 10019, USA. 2. Center for Lymphoid Malignancies, Division of Hematology and Oncology, Department of Medicine, Columbia University Medical Center, 51 West 51st Street, Suite 200, New York, NY, 10019, USA. Jea2149@columbia.edu.
Abstract
PURPOSE OF REVIEW: Peripheral T cell lymphoma is a rare heterogeneous group of diseases which are characterized by poor outcomes to treatment and short overall survival. In the past decade, several new therapies targeting T cell biology have been approved in the relapsed setting. These new therapies, such as pralatrexate, romidepsin, belinostat, and brentuximab vedotin, have begun to make their way into practice. Despite these advances, outcomes have not changed dramatically. In recent years, efforts have been made to incorporate these new therapies into combination strategies to treat this challenging disease entity. Herein we will review some of the latest developments. RECENT FINDINGS: With the new WHO classification, discrete entities of PTCL are now being identified by molecular and phenotypic markers. This new classification is critical to our ability to define disease entities which may respond to certain classes of targeted therapy. Some such mutations include genes controlling epigenetics (TET2, IDH2, DNMT3A, RHOA, CD28). As such, epigenetic therapies such as histone deacetylase (HDAC) inhibitors have become the platform to which other novel therapies or chemotherapy has been added. Early phase clinical studies have demonstrated that combination therapy with romidepsin plus other agents known to have activity in T cell lymphoma have enhanced clinical benefit for this group of diseases. In addition, the antibody drug conjugate, brentuximab vedotin has been shown to have potent activity in T cell lymphomas expressing CD30. This drug is being studied as well with other targeted therapies and chemotherapy in an effort to improve response rates and progression-free survival. Although T cell lymphomas remain a highly challenging group of diseases to treat, new efforts to leverage drugs that discretely target the biology that drives T cell lymphomagenesis in combination provide hope that improved outcomes may be realized in the near future.
PURPOSE OF REVIEW: Peripheral T cell lymphoma is a rare heterogeneous group of diseases which are characterized by poor outcomes to treatment and short overall survival. In the past decade, several new therapies targeting T cell biology have been approved in the relapsed setting. These new therapies, such as pralatrexate, romidepsin, belinostat, and brentuximab vedotin, have begun to make their way into practice. Despite these advances, outcomes have not changed dramatically. In recent years, efforts have been made to incorporate these new therapies into combination strategies to treat this challenging disease entity. Herein we will review some of the latest developments. RECENT FINDINGS: With the new WHO classification, discrete entities of PTCL are now being identified by molecular and phenotypic markers. This new classification is critical to our ability to define disease entities which may respond to certain classes of targeted therapy. Some such mutations include genes controlling epigenetics (TET2, IDH2, DNMT3A, RHOA, CD28). As such, epigenetic therapies such as histone deacetylase (HDAC) inhibitors have become the platform to which other novel therapies or chemotherapy has been added. Early phase clinical studies have demonstrated that combination therapy with romidepsin plus other agents known to have activity in T cell lymphoma have enhanced clinical benefit for this group of diseases. In addition, the antibody drug conjugate, brentuximab vedotin has been shown to have potent activity in T cell lymphomas expressing CD30. This drug is being studied as well with other targeted therapies and chemotherapy in an effort to improve response rates and progression-free survival. Although T cell lymphomas remain a highly challenging group of diseases to treat, new efforts to leverage drugs that discretely target the biology that drives T cell lymphomagenesis in combination provide hope that improved outcomes may be realized in the near future.
Entities:
Keywords:
Antibody drug conjugates; Clinical trials; Epigenetic targeting; HDAC inhibitors; Peripheral T cell lymphoma; Pralatrexate
Authors: Ranjana H Advani; Stephen M Ansell; Mary J Lechowicz; Anne W Beaven; Fausto Loberiza; Kenneth R Carson; Andrew M Evens; Francine Foss; Steven Horwitz; Barbara Pro; Lauren C Pinter-Brown; Sonali M Smith; Andrei R Shustov; Kerry J Savage; Julie M Vose Journal: Br J Haematol Date: 2015-12-02 Impact factor: 6.998
Authors: Georg Hopfinger; Thomas Nösslinger; Alois Lang; Werner Linkesch; Thomas Melchardt; Lukas Weiss; Alexander Egle; Richard Greil Journal: Ann Hematol Date: 2014-01-18 Impact factor: 3.673
Authors: Owen A O'Connor; Steven Horwitz; Tamás Masszi; Achiel Van Hoof; Peter Brown; Jeannette Doorduijn; Georg Hess; Wojciech Jurczak; Poul Knoblauch; Shanta Chawla; Gajanan Bhat; Mi Rim Choi; Jan Walewski; Kerry Savage; Francine Foss; Lee F Allen; Andrei Shustov Journal: J Clin Oncol Date: 2015-06-22 Impact factor: 44.544
Authors: Zhi-Qiang Ning; Zhi-Bin Li; Michael J Newman; Song Shan; Xin-Hao Wang; De-Si Pan; Jin Zhang; Mei Dong; Xin Du; Xian-Ping Lu Journal: Cancer Chemother Pharmacol Date: 2011-11-12 Impact factor: 3.333
Authors: Owen A O'Connor; Barbara Pro; Lauren Pinter-Brown; Nancy Bartlett; Leslie Popplewell; Bertrand Coiffier; Mary Jo Lechowicz; Kerry J Savage; Andrei R Shustov; Christian Gisselbrecht; Eric Jacobsen; Pier Luigi Zinzani; Richard Furman; Andre Goy; Corinne Haioun; Michael Crump; Jasmine M Zain; Eric Hsi; Adam Boyd; Steven Horwitz Journal: J Clin Oncol Date: 2011-01-18 Impact factor: 44.544
Authors: Elise A Olsen; Youn H Kim; Timothy M Kuzel; Theresa R Pacheco; Francine M Foss; Sareeta Parker; Stanley R Frankel; Cong Chen; Justin L Ricker; Jean Marie Arduino; Madeleine Duvic Journal: J Clin Oncol Date: 2007-06-18 Impact factor: 44.544